Applied Digital Corporation vs Boston Scientific Corporation — how do they compare? Applied Digital Corporation trades at $31.87 (market cap $8.55B), while Boston Scientific Corporation trades at $51.1 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 8.7× Applied Digital Corporation's market cap, and Applied Digital Corporation is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| APLD | BSX | |
|---|---|---|
Market Cap | $8.55B | $74.19B |
Sector | Technology | Health |
52-Week High | $49.65 | $108.14 |
52-Week Low | $13.89 | $42.63 |
Enterprise Value | $12.06B | $86.27B |
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $29.06, down 0.55% on the day, with a bearish technical signal and recent earnings misses. The company reported a net loss of $231.07 million in 2025 despite revenue growth, while analyst consensus remains strongly bullish with a $72.36 price target. Recent news highlights significant AI infrastructure contracts and insider selling activity.
Outlook hinges on execution of its $36 billion AI infrastructure pipeline, but risks include high cash burn, negative margins, and rising debt. The stock offers high growth potential if operational targets are met, yet financial sustainability concerns warrant caution for investors amid volatile sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →